| 产品描述: | PROTAC HK2 Degrader-1 is a PROTAC consisting of Lonidamine as a target protein Hexokinase 2 (HK2) inhibitor and Thalidomide as a CRBN ligand-linked PROTAC. PROTAC HK2 Degrader-1 selectively inhibits the proliferation of breast cancer cells by forming a ternary complex through the ubiquitin-proteasome system to degrade Hexokinase 2 (HK2) protein leading to mitochondrial damage and cell death. PROTAC HK2 Degrader-1 effectively inhibits breast tumor growth and reduces the colonic side effects of cisplatin for breast cancer research. |
| 体外研究: |
PROTAC HK2 Degrader-1 抑制 786-O,4T1,PANC-1,HGC-27,MCF-1 细胞增殖的 IC50 分别为 34.07 μM,5.08 μM,31.53 μM,6.11 μM,21.65 μM。 PROTAC HK2 Degrader-1 对 HK2 的 DC50 为2.56 μM (4T1) 和 0.79 μM (MDA-MB-231)。 PROTAC HK2 Degrader-1 (0.01-200 μM, 36 h) 选择性地抑制乳腺癌细胞增殖,并通过泛素介导的蛋白酶体途径,以时间和浓度依赖的方式刺激 HK2 蛋白的降解。 PROTAC HK2 Degrader-1 (10 μM for 4T1, 0.5 μM for MDA-MB-231, 24 h) 通过泛素-蛋白酶体系统形成一个三元复合体降解HK2蛋白。 PROTAC HK2 Degrader-1 (20 μM, 36 h) 降解 HK2 导致线粒体损伤后释放细胞色素 C 激活 caspase-3,裂解 GSDME 引发热昏迷从而细胞释放危险信号,如 ATP、HMGB1、CRT 等,最后导致诱发细胞免疫死亡。 PROTAC HK2 Degrader-1 (20 μM, 36 h) 能诱导 PD-L1 蛋白从细胞膜内化到细胞质,并减少 PD-L1 蛋白的总量。 |
| 体内研究: |
PROTAC HK2 Degrader-1 (50 mg/kg, Intraperitoneal injection, bid, for nine times, six-weekold female BALB/c mice) 需要提及造模动物是什么~)抑制4T1肿瘤模型的肿瘤生长。 PROTAC HK2 Degrader-1 (50 mg/kg, Intraperitoneal injection, bid, for nine times, six-weekold female BALB/c mic 웿 Ů ñ 샮㡽䇘睜⪰ޏࠃ 䇩睜 䇩睜Ȃ Ӥ 晐睦Ӥ 晐睦Ӥ 峀睜 弴睜 ڤ 犐ƈ ڤ郥댻 |
| 参考文献: |
1. Sang R, et al. Degradation of Hexokinase 2 Blocks Glycolysis and Induces GSDME-Dependent Pyroptosis to Amplify Immunogenic Cell Death for Breast Cancer Therapy. J Med Chem. 2023 Jun 27.
|
| 保存条件: |
-20°C |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
1.544 ml |
7.722 ml |
15.444 ml |
| 5 mM |
0.309 ml |
1.544 ml |
3.089 ml |
| 10 mM |
0.154 ml |
0.772 ml |
1.544 ml |
| 50 mM |
0.031 ml |
0.154 ml |
0.309 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |